Antibody Compositions for Solid Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for treating solid tumors, including ovarian cancer, are non-specific, toxic to normal cells, and lead to resistance over time, making them ineffective in advanced stages of the disease.
Innovation Solution
The use of anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin αV antibodies, anti-integrin β1 antibodies, Abciximab, and neutrophil inhibitory factor (NIF) protein, either alone or in combination, to target and inhibit specific cancer cell markers, enhancing treatment efficacy while reducing toxicity and overcoming resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat solid tumors, then tumor cells are killed, but normal rapidly dividing cells are also damaged and resistance develops over time
Solution Approach 1:
The patent segments the treatment approach by using multiple distinct antibodies (anti-CD11b, anti-CD18, anti-MPO, anti-integrin αV, anti-integrin β1) that target different markers on cancer cells. This segmentation allows for differentiated targeting, where each antibody can be selected or combined based on the specific cancer type and patient needs, thereby improving efficacy while potentially reducing overall toxicity through more precise targeting.
Solution Approach 2:
The patent applies local quality by creating compositions with specific antibody combinations tailored to different cancer types and patient conditions. The treatment is not uniform but rather customized to target specific markers expressed in different tumor microenvironments and cancer cell populations, allowing for localized precision therapy that spares normal cells.
2Productivity
If high doses of chemotherapeutic agents are administered, then treatment efficacy increases, but toxicity to normal cells increases
Solution Approach 1:
The patent divides the therapeutic approach into multiple antibody components that can be administered at optimized individual doses. This segmentation allows each antibody to contribute to the overall efficacy at lower individual doses, reducing the cumulative toxicity that would result from a single high-dose chemotherapy regimen.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from non-specific chemical agents to specific biological antibodies. This parameter change enables dose optimization where each antibody can be dosed according to its specific pharmacokinetics and target expression levels, achieving high efficacy through precision rather than through high-dose saturation.
3Duration of action of stationary object
If repeated use of chemotherapeutic agents occurs, then initial treatment effectiveness is achieved, but cancer cells develop resistance
Solution Approach 1:
The patent segments the targeting approach across multiple antibodies that recognize different cell surface markers. This segmentation ensures that when cancer cells develop resistance to one antibody by downregulating its target marker, other antibodies can still effectively bind to their respective markers and kill the cancer cells, thereby preventing resistance development.
Solution Approach 2:
The patent creates a universal treatment platform where multiple antibodies with different mechanisms and targets work together. This multi-functionality ensures that the treatment remains effective against diverse cancer cell populations and prevents resistance by engaging multiple pathways simultaneously, making it difficult for cancer cells to develop escape mechanisms.
4Ease of operation
If single antibody treatment is used, then treatment simplicity is maintained, but broad anti-cancer coverage is limited
Solution Approach 1:
The patent merges multiple antibodies into combined compositions that can be administered together. This merging provides broad anti-cancer coverage by targeting multiple markers simultaneously, while the treatment remains relatively simple as the antibodies are delivered as a coordinated regimen rather than requiring complex sequential administrations.
Solution Approach 2:
The patent creates universal compositions that can be adapted to treat different types of solid tumors by selecting appropriate antibody combinations based on the specific cancer type and marker expression profile. This universality maintains ease of operation through standardized composition formats while achieving broad coverage across multiple cancer indications.
Data Source
AI summary
Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin αV antibodies, anti-integrin β1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.